Primary Mediastinal HER2-positive Apocrine Carcinoma in Mature Teratoma Treated With Anti-HER2 Therapy and Chemoradiation.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Breast Neoplasms
/ drug therapy
Chemotherapy, Adjuvant
Combined Modality Therapy
Docetaxel
/ administration & dosage
Female
Humans
Mediastinal Neoplasms
/ drug therapy
Mediastinum
/ pathology
Neoadjuvant Therapy
Receptor, ErbB-2
/ antagonists & inhibitors
Teratoma
/ drug therapy
Apocrine carcinoma
chemoradiation
mediastinal tumour
pertuzumab
trastuzumab
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
03
12
2018
revised:
13
12
2018
accepted:
14
12
2018
entrez:
27
2
2019
pubmed:
26
2
2019
medline:
6
6
2019
Statut:
ppublish
Résumé
There are no established guidelines for the management of apocrine carcinomas of the breast; they are treated as a non-specific type of breast cancer. We report on the case of a 40-year-old man who developed primary mediastinal apocrine carcinoma overexpressing human epidermal growth factor-2 (HER2). The patient initially underwent complete resection of a mediastinal mature teratoma with a focal apocrine carcinoma component. Two years after surgery, relapse was detected in multiple mediastinal lymph nodes. He received induction chemotherapy including docetaxel, trastuzumab, and pertuzumab; consolidative concurrent chemoradiation was added after six cycles. A complete response was confirmed using computed tomography following this multimodal therapy. After chemoradiation, adjuvant trastuzumab and pertuzumab were administered for 1 year and the patient has since had no evidence of progressive disease. A multi-modal regimen that includes an anti-HER2 agent appears to be a promising treatment for patients with HER2-positive extramammary apocrine carcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
There are no established guidelines for the management of apocrine carcinomas of the breast; they are treated as a non-specific type of breast cancer.
CASE REPORT
METHODS
We report on the case of a 40-year-old man who developed primary mediastinal apocrine carcinoma overexpressing human epidermal growth factor-2 (HER2). The patient initially underwent complete resection of a mediastinal mature teratoma with a focal apocrine carcinoma component. Two years after surgery, relapse was detected in multiple mediastinal lymph nodes. He received induction chemotherapy including docetaxel, trastuzumab, and pertuzumab; consolidative concurrent chemoradiation was added after six cycles. A complete response was confirmed using computed tomography following this multimodal therapy. After chemoradiation, adjuvant trastuzumab and pertuzumab were administered for 1 year and the patient has since had no evidence of progressive disease.
CONCLUSION
CONCLUSIONS
A multi-modal regimen that includes an anti-HER2 agent appears to be a promising treatment for patients with HER2-positive extramammary apocrine carcinoma.
Identifiants
pubmed: 30804140
pii: 33/2/551
doi: 10.21873/invivo.11509
pmc: PMC6506310
doi:
Substances chimiques
Docetaxel
15H5577CQD
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-557Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Breast Cancer. 2002;9(1):43-9
pubmed: 12196721
J Surg Oncol. 2003 May;83(1):24-30
pubmed: 12722093
J Clin Oncol. 2003 Dec 1;21(23):4285-91
pubmed: 14645417
Histopathology. 2008 Jan;52(1):3-10
pubmed: 18171412
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Mod Pathol. 2010 May;23(5):644-53
pubmed: 20208479
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
Breast Cancer. 2013 Jul;20(3):254-61
pubmed: 22274798
Oncologist. 2012;17(9):1135-45
pubmed: 22826373
Clin Breast Cancer. 2015 Apr;15(2):135-42
pubmed: 25454741
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Semin Ultrasound CT MR. 2016 Jun;37(3):196-211
pubmed: 27261345
J Pediatr Hematol Oncol. 2017 Jul;39(5):388-394
pubmed: 28375941
Int J Gynecol Pathol. 2018 Jul;37(4):344-346
pubmed: 28787321
Ann Oncol. 2017 Nov 1;28(11):2761-2767
pubmed: 29112701
Cancer Radiother. 2018 May;22(3):255-263
pubmed: 29673950
Curr Opin Urol. 2018 Sep;28(5):469-473
pubmed: 29939859
Gan No Rinsho. 1987 Jun;33(7):875-80
pubmed: 3613109
J Urol. 1998 Jan;159(1):133-8
pubmed: 9400455